Cost analysis of a nationwide typhoid conjugate vaccine campaign in Burkina Faso Authors: Jean-Louis Koulidiati, Robert L. Zoma, Eric I. Nebié, Soumaila Yameogo, Christelle Neya Ouedraogo, Joël Arthur Kiendrébéogo, Frédéric Debellut, Leonard Uzairue, Leonard Uzairue, Leonard Uzairue, Leonard Uzairue Published: 2026 ABSTRACT BackgroundIn Burkina Faso, typhoid fever remains a major public health concern, particularly among children under 15. In January 2025, a nationwide campaign introduced the typhoid conjugate vaccine targeting children aged 9 months to 14 years. This study aimed to estimate the cost of typhoid conjugate vaccine delivery during the national campaign and to identify the main cost drivers across different administrative levels.MethodsWe conducted a retrospective cross-sectional costing study using a microcosting approach from the perspective of the Ministry of Health. We collected data from fifty health facilities, eight health districts, five health regions, and the national level. Financial and economic costs were estimated for each level, excluding vaccine and syringe costs. All costs were converted to 2024 USD using the official exchange rate. Parameter uncertainty was explored through one-way sensitivity analysis on key assumptions.FindingsVaccinators administered a total of 10.5 million typhoid conjugate vaccine doses. The average financial cost per dose was $0.47 (95% CI: $0.39–$0.51), and the economic cost was $2.16 (95% CI: $1.71–$2.56). Human resources and per diem payments were the main contributors to costs. Costs varied by geography, delivery strategy, and security context, with higher costs observed in rural and conflict-affected areas. The mobile–temporary posts strategy had the highest economic cost per dose ($2.02; 95% CI: $1.64–$2.40), while the fixed strategy had the highest financial cost per dose ($0.41; 95% CI: ($0.32–$0.49). Sensitivity analyses indicated robust cost estimates, with volunteer time valuation having the greatest influence.ConclusionThe financial cost per dose remained within Gavi’s operational support range. The observed cost variations highlight the need for targeted funding and enhanced logistical support to ensure equitable access, particularly in rural and insecure areas. This study provides evidence to inform future vaccination campaigns and supports decision-making for typhoid conjugate vaccine introduction in other countries in the region. Introduction Typhoid fever remains a significant public health challenge globally, with more than 7 million cases and 93,000 deaths estimated in 2021 [1]. The burden of disease is disproportionately high in South Asia and sub-Saharan Africa, where poor sanitation and lack of access to clean water—main transmission routes of the disease—are common [2]. In sub-Saharan Africa, more than three million infections and 33,000 deaths occur annually, with incidence rates reaching up to 383 cases per 100,000 person-years in some countries [3,4]. The region has also seen an increase in typhoid outbreaks, such as the 2023 outbreak in the Democratic Republic of Congo that recorded nearly 1,200 suspected cases, with typhoid intestinal perforations occurring in 3.7% of cases [5]. In response to this persistent threat, the World Health Organization (WHO) recommended the introduction of the typhoid conjugate vaccine (TCV) in endemic countries in 2018. Two vaccines—Typbar TCV® and TYPHIBEV®—are currently available for Gavi-eligible countries in liquid form in five-dose vials [6]. Despite the high disease burden, only five African countries have introduced TCV to date [7]. Burkina Faso faces a substantial typhoid fever burden. Surveillance conducted in 2024 revealed an incidence rate of 133 cases per 100,000 person-years, with rates reaching up to 234 per 100,000 person-years among children aged 2–4 years. Children younger than 15 years, who constitute more than half of the population, accounted for 88% of reported cases [8]. In 2023, the country recorded over 120,000 suspected cases [9]. Progress has been made in disease surveillance, including the establishment of two sentinel sites under the Typhoid Surveillance in Africa Program (TSAP) [10,11], which enabled hospital-based monitoring and blood-culture confirmation. Also, in January 2025, Burkina Faso launched a national TCV campaign targeting children aged 9 months to 14 years old, reaching more than ten million recipients [12]. Following this campaign, the Ministry of Health integrated TCV into its routine immunization program. Understanding the financial and economic costs associated with vaccine delivery is essential for informed decision-making. Financial costs included direct expenditure, while economic costs included the value of all resources used—including volunteer time and donated materials—regardless of financial transactions [13]. Despite its relevance to policymakers, evidence on the costs of TCV introduction remains limited, particularly in Francophone Africa. This study addresses this gap by estimating the costs of TCV delivery during the national introduction campaign in Burkina Faso. The findings provides evidence to support future planning and regional vaccine introduction efforts. Methods Study design We conducted a retrospective cross-sectional costing study using a microcosting approach to estimate both financial and economic costs of the national TCV campaign in Burkina Faso. We adopted the perspective of the Ministry of Health, covering the campaign period—from preparatory activities to post-campaign review. Study sites and sampling Burkina Faso’s health system is a hierarchical pyramid structure, comprised of 13 health regions, 70 health districts, and approximately 2,670 Health and Social Promotion Centers (CSPS), which serve as the primary level of care and the first point of contact for communities. All CSPS involved in the national vaccination campaign formed the sampling frame. We used a stratified random sampling approach and the EPIC Sample Design Optimizer (SDO) tool [14] to randomly select 5 regions, 8 districts, and 50 CSPS for inclusion. The 50 CSPS from 5 regions were chosen based on budgetary constraints. We stratified the sample based on urban versus rural location. Data collection Data collection took place in March 2025, two months after the campaign ended, to reduce recall bias. Prior to fieldwork, data collectors received training on the use of standardized data collection tools. They conducted visits at selected CSPS, district health offices, regional directorates, and the Ministry of Health central level. Due to security concerns, we replaced five inaccessible CSPS with alternative facilities matched on key characteristics. Replacement facilities were selected based on catchment area population size and the number of measles vaccine doses administered in 2024, with further stratification by urban or rural location. Enumerators collected primary data through interviews with key informants, including head nurses, Expanded Programme on Immunization (EPI) focal points, district and regional health managers, and staff from the Directorate of Vaccination Prevention (at the central level). Tailored questionnaires for each level captured information on campaign activities and cost categories as described in Table 1. 10.1371/journal.pone.0351148.t001Table 1Campaign activities and cost categories.Campaign activitiesCost categoriesFinancial costOpportunity costCampaign managementMeeting and eventsHuman resourcesTrainingFuel, maintenance, and energyCapital costs for vehicles and equipmentVaccine service deliveryVehicle rental and transportationVaccine distribution and storagePrinting stationeries and communicationsSupervisionSuppliesCold chain maintenancePer diemWaste managementAEFI1 managementRecord keeping and monitoringSocial mobilization1 Adverse Events followed immunization. Campaign activities and cost categories. 1 Adverse Events followed immunization. Secondary data focused on unit prices, such as salary scales for campaign personnel and replacement costs for equipment and vehicles, sourced from government and international organizations (Appendix 1 in S1 File). Data analysis At each administrative level, we estimated the financial and economic costs of vaccine delivery for the campaign. We multiplied resource quantities by unit prices or opportunity costs to estimate activity-specific costs. Additionally, we calculated delivery costs by campaign activity and cost category excluding vaccine procurement and consumables (i.e., auto-disable syringes, safety boxes). Then, we aggregated costs per dose for each administrative level [15–17]. At the CSPS level, we calculated weighted average costs to obtain overall cost estimates. Furthermore, we calculated costs per dose by administrative level, delivery strategy, and geographic setting (urban or rural) and security status (conflict-affected or non conflict-affected zones). We collected all costs in West African CFA francs and converted them to 2024 USD using the World Bank exchange rate (1 USD = 606.35 FCFA) [18]. We annualized capital costs using replacement values, expected useful life, and a 3% discount rate (Appendix 2 in S1 File) [17]. We assessed uncertainty around cost estimates using sampling-based variance across sampled facilities. We calculated standard errors were based on the variability in cost estimates across the sampled administrative levels. We constructed 95% confidence intervals using the normal approximation. We explored parameter uncertainty through one-way sensitivity analysis on key assumptions, including the discount rate, valuation of volunteer time, and replacement costs of capital items. We also conducted a scenario analysis excluding facilities replaced due to security constraints. We performed data analysis using Stata version 14 (StataCorp, TX, USA). Reporting follows CHEERS 2022 guidelines for economic evaluations (S2 File). Ethical considerations Burkina Faso’s Health Research Ethics Committee granted ethical approval (Deliberation No. 2025-02-035) and the Ministry of Health approved the study. We secured oral informed consent from all participants. Results Description of the study sample characteristics The study sample comprised 50 CSPS, 8 health districts, 5 regions, and the central level. Of the 50 selected CSPS, 74% were in rural areas, and 28% were in conflict-affected zones. Three CSPS (6%) also administered 212 doses of HPV and 14 doses of MR vaccines in addition to TCV, representing less than 1% of total doses. We excluded these doses from the analysis. Nearly all CSPS (98%) implemented all three delivery strategies during the campaign. The mobile and temporary posts strategy—conducted in schools, markets, churches and mosques —was predominant, accounting for 50% of doses administered, followed by outreach at regular posts (35%), and the fixed strategy (15%). Campaign costs Tables 2 and 3 present the financial and economic costs incurred across administrative levels. At the CSPS level, the weighted average financial cost was $2,164, and the economic cost was $12,054. Service delivery accounted for the largest share of economic costs (41%), followed by social mobilization (24%). Per diems represented 89% of financial costs, while human resources contributed 81% of economic costs. Across all 50 CSPS, a total of 439,601 TCV doses were administered, with an average of 8,792 doses per facility. The financial cost per dose was $0.39 (95% CI: $0.31–$0.40), and the economic cost per dose was $1.90 (95% CI: $1.62–$2.18). 10.1371/journal.pone.0351148.t002Table 2Number of doses delivered and campaign cost.Health facility level (n = 50)District level (n = 8)Regional level (n = 5)National level(n = 1) Total TCV doses delivered 439 6012 068 5605 568 49310,552,806 Financial cost of campaign $ 2,164Weighted mean cost$ 5,277Mean cost$ 7,759Mean cost$ 896,035 Economic cost of campaign $ 12,054Weighted mean cost$ 40,209Mean cost$ 22,363Mean cost$ 966,274 Main activity driving cost Service deliverySocial mobilizationSupervisionCampaign managementTrainingSupervisionCampaign managementSocial mobilizationRecord keeping and monitoringSocial mobilizationSupervision Main cost category driving cost Human resourcesPer DiemHuman resourcesHuman resourcesPer DiemPrinting, communications, and stationeryPer Diem Number of doses delivered and campaign cost. 10.1371/journal.pone.0351148.t003Table 3Cost per TCV dose delivered.Health facility levelDistrict levelRegional levelNational levelAll levelsMean financial cost (95% CI)$0.35($0.31; $0.40)$0.02($0.01; $0.03)$0.01($0.00; $0.01)$0.09 $0.47 ($0.39; $0.51) Mean economic cost (95% CI)$1.90($1.62; $2.18)$0.15($0.01; $0.28)$0.02($0.01; $0.03)$0.09 $2.16 ($1.71; $2.56) Cost per TCV dose delivered. At the district level, the average financial cost was $5,277, and the average economic cost was $40,209. Supervision and campaign management were the activities with the highest shares of both financial and economic costs. Human resources accounted for 85% of economic costs. Vaccinators administered 2,068,560 doses across the eight districts, resulting in a financial cost per dose of $0.02 (95% CI: $0.01–$0.03) and an economic cost per dose of $0.15 (95% CI: $0.01–$0.28). At the regional level, the average financial cost was $7,759, and the average economic cost was $22,363. Supervision and campaign management were again the dominant cost activities, accounting for 48% and 22% of economic costs, respectively. Human resources (61%) and per diems (19%) were the largest cost categories. A total of 5,568,493 doses were administered in the five regions, with a financial cost per dose of $0.01 (95% CI: $0.00–$0.01) and an economic cost per dose of $0.02 (95% CI: $0.01–$0.03). At the central level, the financial cost was $893,860 and the economic cost was $964,099. Data management and social mobilization were the main activities driving costs. Printing, communications, and stationery accounted for 65% of financial costs and 61% of economic costs, followed by per diems (15% and 14%, respectively). Nationally, 10,552,806 doses were administered, with both financial and economic costs per dose estimated at $0.09. Across all levels, the average financial cost per TCV dose was $0.47 (95% CI: $0.39–$0.51), and the economic cost was $2.16 (95% CI: $1.71–$2.56) (Table 3). Cost distribution by activity and cost category Fig 1 illustrates the breakdown of economic cost per dose by activity and cost category. Vaccine administration and social mobilization contributed $0.79 (37%) and $0.47 (22%) of the $2.16 economic cost per dose, respectively. Human resources accounted for $1.69 (78%) and per diems for $0.32 (15%). Economic cost distribution by activity and cost category.. Cost variation by geography, delivery strategy, and security context Table 4 shows cost variations by CSPS location, security status, and delivery strategy. Financial cost per dose was higher in rural areas ($0.40; 95% CI: $0.34–$0.45) than urban areas. The fixed strategy had the highest financial cost per dose ($0.41; 95% CI: $0.32–$0.49), while the mobile and temporary posts strategy had the highest economic cost ($2.02; 95% CI: $1.64–$2.40). CSPS in conflict-affected zones had a higher financial cost per dose ($0.39; 95% CI: $0.34–$0.44) than those in non-conflict-affected zones. 10.1371/journal.pone.0351148.t004Table 4Cost per TCV dose by geography, delivery strategy, and security level (2024 USD).Weighted mean financial cost (95% CI)Weighted mean economic cost (95% CI) Geography Urban 0.30 (0.24; 0.36)2.12 (1.56; 2.68) Rural 0.40 (0.34; 0.45)1.74 (1.48; 1.99) Delivery strategy Fixed 0.41 (0.32; 0.49)1.89 (1.56; 2.23) Outreach at regular posts 0.34 (0.28; 0.40)1.78 (1.52; 2.04 Mobile-Temporary posts 0.36 (0.30; 0.41)2.02 (1.64; 2.40) Security status Conflict-affected health facilities 0.39 (0.34;0.44)1.70 (1.29; 2.10) Non-conflict-affected health facilities 0.34 (0.28; 0.40)1.99 (1.64; 2.34) Total 0.35 (0.31; 0.40) 1.90 (1.62; 2.18) Cost per TCV dose by geography, delivery strategy, and security level (2024 USD). Regional disparities and dose-cost relationship Among the five regions, the East region had the highest financial cost per dose ($0.63), while the North region had the lowest ($0.39). The Hauts-Bassins region recorded the lowest economic cost per dose ($1.94), whereas the East had the highest ($2.53) (Fig 2). Financial and economic cost per dose by region. Fig 3 shows the relationship between the number of doses administered and the associated costs at the CSPS level. The financial cost per dose decreased as the number of doses administered increased. Relationship between costs and volume delivered at health facility level. Sensitivity and scenario analysis The sensitivity analysis indicated that the valuation of volunteer time had the greatest impact on the estimated cost per dose. Varying this parameter by ±20% resulted in a three percent change in the economic cost per dose, ranging from $ 2.13 (95% CI: $1.62–$2.46) to $ 2.19 (95% CI: $1.67–$2.52). Also, excluding inaccessible health facilities from the analysis did not change the financial cost per dose, which remained at $ 0.47. However, the economic cost per dose slightly increased by 1.4%, from $ 2.16 in the base-case analysis to $ 2.19 (95% CI: $1.67–$2.53).(Appendix 3 in S1 File). Discussion This study estimates the financial and the economic costs of the national TCV campaign in Burkina Faso, covering all levels of the health system. The findings reveal substantial variability in cost per dose across administrative levels, geographic settings, and delivery strategies, offering critical insights for future immunization planning. The average financial cost per dose of $0.47 observed in this study is lower than estimates from similar campaigns in other low- and middle-income countries. For instance, a typhoid outbreak response (TCV campaign) in Zimbabwe in 2019 reported a financial cost of $0.79 per dose [19], while Malawi’s 2023 integrated campaign yielded a financial cost per dose of $0.49 per dose [20]. The lower cost in Burkina Faso may be attributed to the strategic use of existing infrastructure and the implementation of multiple delivery approaches, which enhanced operational efficiency. Importantly, the financial cost per dose remains within the operational support range provided by Gavi ($0.45–$0.65) [21], suggesting that the campaign was financially viable under current donor frameworks. Nevertheless, the observed cost variability underscores the importance of context-specific budgeting and resource allocation. A key finding is the predominance of human resources and per diems as cost drivers. Human resources accounted for the majority of economic costs, while per diems dominated financial costs. This pattern aligns with previous studies conducted in similar settings [21–23], where labor-intensive activities significantly influence immunization costs. Vaccine administration emerged as the main activity contributing to economic costs, followed by social mobilization. The latter’s prominence is unique compared to other campaign cost studies [19,20,22]. This reflects the substantial investment made during the campaign to address vaccine hesitancy and engage communities, political leaders, and education stakeholders. This emphasis on communication and outreach is particularly relevant given the increasing skepticism toward vaccines in various contexts. At the central level, data management was the most resource-intensive activity, driven largely by the printing of over eleven million vaccination cards. This finding highlights the need to explore cost-saving alternatives, such as digital data collection and reporting systems, which could streamline operations and reduce expenditure. Furthermore, the analysis also revealed that the fixed strategy incurred the highest financial cost per dose, likely due to the lower volume of doses administered through this approach. This suggests the presence of economies of scale [22], where higher throughput leads to reduced unit costs. Conversely, the economic cost per dose for the fixed strategy was lower than for mobile and temporary posts and outreach at regular posts strategies, possibly due to reduced reliance on additional human resources. Regional disparities in cost were notable, with the East, Centre-North, and North regions—areas affected by insecurity—recording the highest economic costs. These elevated costs are probably due to increased logistical challenges and the need for additional personnel to ensure safe and effective vaccine delivery [22]. The higher opportunity costs in these regions further contribute to the overall economic burden. These findings emphasize the importance of tailoring campaign strategies and resource allocation to the specific needs of vulnerable and hard-to-reach populations. The inverse relationship between the number of doses administered and financial cost per dose at the CSPS level further supports the existence of economies of scale [22]. Facilities administering larger volumes of vaccines achieved lower per-dose costs, reinforcing the value of optimizing delivery efficiency in future campaigns. The generalizability of these findings should be interpreted in light of the specific contextual features of Burkina Faso. While some cost drivers—such as increased transport and logistical costs in conflict-affected zones—are context-specific to Burkina Faso, key findings are likely transferable. In particular, the dominance of human resources and per diem payments as major cost drivers, as well as variations by delivery strategy and economies of scale, is consistent with evidence from other low-income settings. Policy implications The findings of this study offer actionnable evidence for immunization policy and strategic planning. First, the high costs observed in rural and conflict-affected zones underscore the need for targeted financial and logistical support to ensure equitable vaccine access during campaigns. Tailored resource allocation strategies are essential to address geographic and security-related disparities. Second, the substantial contribution of human resources to overall economic costs highlight the importance of investing in workforce development. Policymakers should prioritize training, retention, and efficient deployment of health personnel. Strengthening Burkina Faso’s community health strategy [24] could be instrumental in building a cadre of trained, community-based health workers capable of delivering essential services, including vaccination. Third, the study identified data management—particularly at the central level—as a major cost driver. Transitioning to digital health information systems for real-time monitoring and evaluation could improve operational efficiency and reduce expenditures associated with printing and manual data handling [25]. Study limitations This study has several limitations. First, the retrospective nature of data collection may introduce recall bias or incomplete reporting. However, conducting data collection within two months of the campaign likely minimized this risk. Second, as the analysis adopted an incremental campaign costing approach, we did not include depreciation of long-term infrastructure (EPI building,office infrastructure) which may lead to underestimation of total economic costs. Third, economic costs included estimates for volunteer time, but these may have been underreported due to reliance on self-reported data and lack of standardized valuation methods for non-financial contributions. Finally, due to insecurity, five CSPS were replaced with alternatives. This substitution may have introduced selection bias, but we selected facilities likely close in cost structure or campaign implementation to the replacing ones to reduce this bias. Moreover, the scenario analysis excluding these health facilities indicated that their replacement had no substantial impact on either financial or economic costs estimates. Conclusion This study estimates of the financial and economic costs of the national TCV campaign in Burkina Faso. The average financial cost per dose fell within the operational support range provided by Gavi, indicating financial feasibility. Human resources and per diems were the major cost drivers. Geographic and contextual variations in cost highlight the need for adaptive planning and targeted support. These findings offer valuable evidence to inform future vaccination campaigns and support TCV introduction in other countries facing similar public health challenges. Supporting information Overview of the campaign costs estimation and sensitivity and scenario analysis results. (DOCX) CHEERS Reporting checklist. (DOCX) Supporting information for data availability. (DOCX) 4 Mar 2026 -->PONE-D-25-66817-->-->Cost analysis of a nationwide typhoid conjugate vaccine campaign in Burkina Faso-->-->PLOS One Dear Dr. Koulidiati, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.-->--> -->-->Kindly ensure to examine all the comments from the reviewers and provide a point by point responses to their comments.-->--> -->-->Please submit your revised manuscript by Apr 18 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Leonard Ighodalo Uzairue, PhD Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. 3. Thank you for stating the following financial disclosure: “This work was undertaken as part of the Typhoid Vaccine Acceleration Consortium (TyVAC). TyVAC is a partnership between the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine; the Oxford Vaccine Group at the University of Oxford; and PATH, an international nonprofit. This work was supported, in whole or in part, by the Gates Foundation [INV-030857]. Under the grant conditions of the Gates Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. J-LK, as an independent consultant and RLZ, DAVYCAS International staff, received consulting fees from PATH.” Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 4. For studies involving third-party data, we encourage authors to share any data specific to their analyses that they can legally distribute. PLOS recognizes, however, that authors may be using third-party data they do not have the rights to share. When third-party data cannot be publicly shared, authors must provide all information necessary for interested researchers to apply to gain access to the data. (https://journals.plos.org/plosone/s/data-availability#loc-acceptable-data-access-restrictions) For any third-party data that the authors cannot legally distribute, they should include the following information in their Data Availability Statement upon submission: 1) A description of the data set and the third-party source 2) If applicable, verification of permission to use the data set 3) Confirmation of whether the authors received any special privileges in accessing the data that other researchers would not have 4) All necessary contact information others would need to apply to gain access to the data 5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. 6. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 3 in your text; if accepted, production will need this reference to link the reader to the Table. 7. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments: Thank you for the study; it is quite an interesting manuscript to read. However, I have some few concerns. First, there is a need to discuss what 'financial and economic cost' means. You need to bring that in your introduction and also state how it was determined in the method section, because you used it quite a lot in the abstract. Also, there are inconsistencies in the denominator used, so you need to revisit that and make it consistent. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: I Don't Know Reviewer #4: Yes ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: No Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: Overall assessment This manuscript makes a strong and timely contribution to the vaccine delivery costing literature by presenting a detailed microcosting analysis of a nationwide typhoid conjugate vaccine (TCV) campaign in Burkina Faso. Large-scale, empirically grounded costing studies of vaccination campaigns—particularly in low-income and insecure settings—remain relatively rare, and this paper substantially advances the evidence base. The nationwide scope, use of a bottom-up microcosting approach across administrative levels, and explicit attention to cost variation by delivery strategy and security context are major strengths. The study is well aligned with the article’s stated objectives and is highly relevant for immunization program planners and financing partners. Overall, the manuscript is suitable for publication after moderate revisions focused on clarity, transparency, and interpretation, rather than expansion into cost-effectiveness analysis. Major strengths 1. Substantive contribution through microcosting The use of a microcosting approach across health facility, district, regional, and national levels is a major strength and the paper’s core contribution. Few published studies capture delivery costs at this level of granularity for a nationwide campaign of this scale. The approach is appropriate, clearly motivated, and well matched to the study objectives. 2. Scale and empirical rigor The analysis is grounded in a campaign that delivered over 10 million doses, drawing on data from multiple administrative levels. This scale gives the findings strong empirical credibility and makes the resulting unit costs highly policy-relevant. The inclusion of both financial and economic costs further strengthens the analysis. 3. Policy relevance and operational insight The disaggregation of costs by: • delivery strategy (fixed, mobile, temporary), • geography (urban vs. rural), • and security context provides actionable insights for campaign design and budgeting. Identifying human resources and per diem payments as dominant cost drivers is consistent with prior campaign experience and reinforces the practical value of the findings. 4. Clear presentation of unit costs Reporting costs per dose with confidence intervals and benchmarking financial costs against Gavi operational support ranges enhances interpretability and usability for decision-makers. The results are presented clearly and concisely. Suggestions for improvement These comments are intended to strengthen transparency and interpretability, not to change the study’s scope. 1. Clarify key microcosting assumptions The manuscript would benefit from additional detail on: • How shared or overhead costs (e.g., planning, supervision) were allocated across doses or administrative levels. • Methods used to annualize capital costs and assumptions about useful life. • How staff time and opportunity costs were valued for economic cost estimates. These clarifications could be addressed succinctly in a methods appendix or supplementary table and would improve reproducibility. 2. Expand description of uncertainty estimation While confidence intervals are reported, the paper should briefly explain: • The statistical method used to generate them (e.g., bootstrapping, sampling-based variance). • What sources of uncertainty are captured (sampling only vs. parameter uncertainty). This would strengthen readers’ confidence in the precision of the estimates. 3. Improve discussion of generalizability Given the unique security and logistical context of Burkina Faso, the discussion could more explicitly address: • Which cost components are likely context-specific. • Which findings (e.g., dominance of HR and per diems) are likely transferable to other low-income settings. This would help readers appropriately interpret and apply the results elsewhere. 4. Minor clarity and consistency issues A careful editorial pass could improve: • Consistency in terminology across sections (e.g., delivery strategy labels). • Clearer signposting between financial vs. economic cost results. • Minor typographical and formatting issues. Conclusion This is a high-quality costing study that fills an important gap in the literature on vaccine campaign delivery costs. Its primary contribution lies in the depth and rigor of the microcosting analysis, not in extending to cost-effectiveness modeling—and it should be evaluated on those terms. With targeted revisions to improve methodological transparency and discussion, the manuscript will provide a valuable reference for policymakers, donors, and researchers planning future vaccination campaigns. Reviewer #2: This manuscript presents a technically sound and well-executed cost analysis of a nationwide typhoid conjugate vaccine campaign in Burkina Faso. The retrospective micro-costing approach, conducted from the government perspective across multiple administrative levels; 50 health facilities, 8 districts, 5 regions, and the national level, is appropriate for the study objectives. The data support the conclusions regarding average financial and economic cost per dose, the identification of human resources and per diem payments as key cost drivers, and observed cost variation by geography, delivery strategy, and security context. The statistical analyses are appropriate and clearly reported, including weighted cost estimates and 95% confidence intervals, with stratified analyses by urban–rural setting and delivery strategy. Ethical approval and informed consent procedures are documented, and data availability is addressed in line with PLOS ONE requirements. Although, minor clarifications may be recommended to harmonize the Data Availability Statement to briefly describe the method used to derive confidence intervals and clarify the potential impact of replacing inaccessible health facilities due to security constraints. Overall, the manuscript meets PLOS ONE’s criteria for publication, and no substantive scientific concerns remain. Reviewer #3: This manuscript presents a microcosting analysis of Burkina Faso's national typhoid conjugate vaccine (TCV) campaign conducted in January 2025, which reached 10.5 million children aged 9 months to 14 years. The study estimates financial costs at $0.47 per dose and economic costs at $2.16 per dose, demonstrating that campaign delivery costs fall within Gavi operational support ranges. The multi-level sampling approach and stratification by geography, delivery strategy, and security context provide valuable granularity for policy planning.This addresses an important evidence gap, as TCV costing data from francophone Africa are extremely limited despite high typhoid burden. The methodology is generally sound and findings have clear policy relevance for ministries of health, Gavi, and WHO. However, several methodological clarifications and expansions are needed before publication. Major comments 1. Inconsistent Dose Denominators Issue: The manuscript reports conflicting total dose numbers: Abstract and line 197: 10,552,806 doses Abstract line 38: "10.5 million doses" Table 2: 11,422,855 doses nationally Impact: All per-dose cost calculations depend on the correct denominator. This inconsistency undermines confidence in the primary outcome. Please Reconcile these figures and explain any discrepancy (e.g., incomplete reporting from non-sampled districts) Use consistent denominator throughout Recalculate all per-dose costs if necessary Verify Table 3 calculations align with corrected denominators 2. Uncertainty Quantification Insufficient Issue: 95% confidence intervals are presented but methodology is not described. No sensitivity analyses are provided despite multiple assumptions (discount rate, volunteer time valuation, vehicle replacement costs, useful life). I suggest an additional Methods subsection describing CI calculation (bootstrap? parametric assumptions? accounting for clustering?) Conduct one-way sensitivity analyses on key parameters: Discount rate (0%, 3%, 5%) Volunteer wage assumptions Vehicle/equipment replacement costs 3. Capital Cost Treatment and Shared Infrastructure Issue: The authors acknowledge excluding "depreciation of long-term infrastructure" (line 309-310) but do not specify which items. It's unclear whether this represents: Incremental campaign costs only, or Full economic costs excluding pre-existing infrastructure Impact: Affects comparability with other studies and interpretation of economic costs. Specify which capital items were excluded (cold chain equipment? storage facilities? EPI buildings?) State clearly whether the perspective is incremental campaign cost vs. average cost including shared infrastructure Justify exclusions based on whether infrastructure was campaign-specific or shared with routine immunization If feasible, provide sensitivity estimate including shared infrastructure costs. MINOR CONCERNS Methods and Reporting Line 72: Specify which TCV vaccine (Typbar TCV® or TYPHIBEV®) was used in Burkina Faso Lines 97-98: Standardize terminology as "microcosting" (no hyphen) throughout Line 120: Describe replacement protocol for 5 inaccessible CSPS more rigorously. What specific matching criteria were used? Conduct sensitivity analysis excluding these sites. Line 153: Clarify how oral consent was documented Add to Methods: "Reporting follows CHEERS 2022 guidelines for economic evaluations" and include completed checklist as supplementary file Reviewer #4: Title: Cost analysis of a nationwide typhoid conjugate vaccine campaign in Burkina Faso This study is very important in ensuring that scarce resources are judiciously used especially in resource limited country like Burkina Faso. This is my comment. The definition of financial cost and economic cost should be included in the introduction because it will give the reader a better understanding of the cost estimate of administering the vaccine in Burkina Faso. ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: Yes: Idowu Michael Ariyibi Reviewer #3: No Reviewer #4: Yes: Dr Abdulahi Ayanwale ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. Submitted filename: PLOS Article review on Vaccine Burkina Faso.odt 22 Apr 2026 Dear Editor, We thank you, the PlosOne editorial team and all the reviewers for the insightful and constructive comments to our submission. We have revised the manuscript substantially in response to the comments, to enhance its clarity, transparency, and interpretability. Below, we respond to each comment point-by-point. Editor and reviewers comments are reproduced in regular font, followed by our responses in bold; important substantive changes to the manuscript are also included in italic. Editor comments Thank you for the study; it is quite an interesting manuscript to read. However, I have some few concerns. First, there is a need to discuss what 'financial and economic cost' means. You need to bring that in your introduction and also state how it was determined in the method section, because you used it quite a lot in the abstract. Also, there are inconsistencies in the denominator used, so you need to revisit that and make it consistent. We added the definition of financial cost and economic cost in the introduction section and explain how they were estimated in the method section and in supporting information. Also, we thank the editor for identifying this inconsistency in the denominator. The correct one is 10,552,806 doses, corresponding to the validated dataset used for all cost analyses. Review Comments to the Author Reviewer #1: We thank the reviewer for the encouraging and thoughtful review, and for recognizing the major strengths, and policy relevance of the study. 1. Clarify key microcosting assumptions The manuscript would benefit from additional detail on: • How shared or overhead costs (e.g., planning, supervision) were allocated across doses or administrative levels. Response to Reviewer #1: The purpose of the study is to estimate TCV campaign specific costs. We estimate these costs at each administrative level by quantifying ressources used for each campaign activity. For shared resources, tracing factors (allocation rules) were used to attribute costs to TCV campaign. These tracing factors included staff time allocated to the campaign, percentage of vehicle and equipment capacity utilized during the campaign, or the number of doses and the volume of other vaccines administered or interventions delivered as part of the campaign. • Methods used to annualize capital costs and assumptions about useful life. Response to Reviewer #1: To reflect their use over multiple years, capital items (e.g. cold chain equipment, vehicles, and durable equipment) were annualized using an annualization factor (see formula below) with a discount rate (r) and an assumed useful life (n) for capital items. The annualized cost was allocated to the campaign based on the proportion of time the asset was used during campaign activities. • How staff time and opportunity costs were valued for economic cost estimates. Response to the reviewer #1: For economic cost estimates, staff time was valued using an opportunity cost approach. Time allocated to campaign activities was obtained through interviews with health personnel and program managers and multiplied by the corresponding gross salary to estimate the economic value of personnel time. These clarifications could be addressed succinctly in a methods appendix or supplementary table and would improve reproducibility. Response to the reviewer #1: We added a supplementary file explaining these clarifications on the estimation of the campaign costs. 2. Expand description of uncertainty estimation While confidence intervals are reported, the paper should briefly explain: • The statistical method used to generate them (e.g., bootstrapping, sampling-based variance). • What sources of uncertainty are captured (sampling only vs. parameter uncertainty). This would strengthen readers’ confidence in the precision of the estimates. We have revised the Methods section (lines 158-166) to clearly describe how confidence intervals were generated. Specifically, 95% confidence intervals were calculated using sampling-based variance derived from the study sample, with standard errors estimated from the variability in cost estimates across sampled administrative levels. Confidence intervals were constructed using the normal approximation. These intervals capture sampling uncertainty related to the selection of study sites, but do not incorporate parameter uncertainty. Therefore we conducted one-way sensitivity analyses on key parameters (discount rate, volunteer wage and vehicle and equipment replacement costs). This clarification has been added to the Methods section: «Uncertainty around cost estimates was assessed using sampling-based variance derived from the study sample. Standard errors were calculated based on the variability in cost estimates across the sampled administrative levels. 95% confidence intervals were constructed using the normal approximation. Parameter uncertainty was explored through one-way sensitivity analysis on key assumptions, including the discount rate, valuation of volunteer time, and replacement costs of capital items (supplementary file ). Also, we conduct a scenario analysis by removing the replaced facilities due to security constraints from the analysis.» 3. Improve discussion of generalizability Given the unique security and logistical context of Burkina Faso, the discussion could more explicitly address: • Which cost components are likely context-specific. • Which findings (e.g., dominance of HR and per diems) are likely transferable to other low-income settings. This would help readers appropriately interpret and apply the results elsewhere. We appreciated the suggestion and have expanded the Discussion section to include cost components likely context-specific and those transferable to low-and-middle income countries (see lines 332-338): «The generalizability of these findings should be interpreted in light of the specific contextual features of Burkina Faso. While some cost drivers—such as increased transport and logistical costs in conflict-affected areas—are context-specific to Burkina Faso, key findings are likely transferable. In particular, the dominance of human resources and per diem payments as major cost drivers, as well as variations by delivery strategy and economies of scale, are consistent with evidence from other low-income settings.» 4. Minor clarity and consistency issues A careful editorial pass could improve: • Consistency in terminology across sections (e.g., delivery strategy labels). • Clearer signposting between financial vs. economic cost results. • Minor typographical and formatting issues. All minor comments have been addressed as follows: We have improved the clarity of presentation by consistently distinguishing between financial and economic costs throughout the manuscript. Separate subheadings and explicit terminology are now used to guide the reader, and additional explanations have been included to clarify the conceptual differences between these two cost measures. Reviewer #2: We thank the reviewer for the constructive review of the manuscript. Below we address the clarifications suggested. Briefly describe the method used to derive confidence intervals: We have revised the Methods section (lines 158-166) to clearly describe how confidence intervals were generated. Specifically, 95% confidence intervals were calculated using sampling-based variance derived from the study sample, with standard errors estimated from the variability in cost estimates across sampled administrative levels. Confidence intervals were constructed using the normal approximation. These intervals capture sampling uncertainty related to the selection of study sites, but do not incorporate parameter uncertainty. Therefore we conducted one-way sensitivity analyses on key parameters (discount rate, volunteer wage and vehicle and equipment replacement costs). This clarification has been added to the Methods section: «Uncertainty around cost estimates was assessed using sampling-based variance derived from the study sample. Standard errors were calculated based on the variability in cost estimates across the sampled administrative levels. 95% confidence intervals were constructed using the normal approximation. Parameter uncertainty was explored through one-way sensitivity analysis on key assumptions, including the discount rate, valuation of volunteer time, and replacement costs of capital items (supplementary file ). Also, we conduct a scenario analysis by removing the replaced facilities due to security constraints from the analysis.» Clarify the potential impact of replacing inaccessible health facilities due to security constraints. In the study limitations section (lines 368-373) we have a short paragraph acknowledging that five health facilities were inaccessible due to security constraints and were replaced with accessible facilities considered comparable in terms of cost structure or campaign implementation (similar catchment area population, number of doses delivered). Moreover, we added a scenario analysis excluding these health facilities. This analysis indicated that their replacement had no substantial impact on either financial or economic costs estimates (See lines 270-274). Reviewer #3: We thank the reviewer for the positive evaluation of the manuscript’s relevance, strengths, as well as for the detailed and constructive suggestions. Below we address the suggested comments. 1. Inconsistent Dose Denominators Issue: The manuscript reports conflicting total dose numbers: Abstract and line 197: 10,552,806 doses Abstract line 38: "10.5 million doses" Table 2: 11,422,855 doses nationally Impact: All per-dose cost calculations depend on the correct denominator. This inconsistency undermines confidence in the primary outcome. Please Reconcile these figures and explain any discrepancy (e.g., incomplete reporting from non-sampled districts) Use consistent denominator throughout Recalculate all per-dose costs if necessary Verify Table 3 calculations align with corrected denominators We thank the reviewer for identifying this inconsistency. The correct denominator is 10,552,806 doses, corresponding to the validated dataset used for all cost analyses. The higher figure previously reported in Table 2 (11,422,855 doses) reflected an earlier, uncleaned version of the national dataset and has now been corrected. All per-dose cost estimates, including those in the Abstract and Table 3, were calculated using the correct denominator; therefore, no recalculation was required. 2. Uncertainty Quantification Insufficient Issue: 95% confidence intervals are presented but methodology is not described. No sensitivity analyses are provided despite multiple assumptions (discount rate, volunteer time valuation, vehicle replacement costs, useful life). I suggest an additional Methods subsection describing CI calculation (bootstrap? parametric assumptions? accounting for clustering?) Conduct one-way sensitivity analyses on key parameters: Discount rate (0%, 3%, 5%) Volunteer wage assumptions Vehicle/equipment replacement costs We have revised the Methods section to clearly describe how confidence intervals were generated. Specifically, 95% confidence intervals were calculated using sampling-based variance derived from the study sample, with standard errors estimated from the variability in cost estimates across sampled administrative levels. Confidence intervals were constructed using the normal approximation. These intervals capture sampling uncertainty related to the selection of study sites, but do not incorporate parameter uncertainty. Therefore we conducted one-way sensitivity analyses on key parameters (discount rate, volunteer wage and vehicle and equipment replacement costs). This clarification has been added to the Methods section: «Uncertainty around cost estimates was assessed using sampling-based variance derived from the study sample. Standard errors were calculated based on the variability in cost estimates across the sampled administrative levels. 95% confidence intervals were constructed using the normal approximation. Parameter uncertainty was explored through one-way sensitivity analysis on key assumptions, including the discount rate, valuation of volunteer time, and replacement costs of capital items (supplementary file ). Also, we conduct a scenario analysis by removing the replaced facilities due to security constraints from the analysis.» 3. Capital Cost Treatment and Shared Infrastructure Issue: The authors acknowledge excluding "depreciation of long-term infrastructure" (line 309-310) but do not specify which items. It's unclear whether this represents: Incremental campaign costs only, or Full economic costs excluding pre-existing infrastructure Impact: Affects comparability with other studies and interpretation of economic costs. Specify which capital items were excluded (cold chain equipment? storage facilities? EPI buildings?) State clearly whether the perspective is incremental campaign cost vs. average cost including shared infrastructure Justify exclusions based on whether infrastructure was campaign-specific or shared with routine immunization If feasible, provide sensitivity estimate including shared infrastructure costs. We have revised the manuscript to clarify the costing perspective and the treatment of capital and shared infrastructure costs (lines 333-334). The analysis adopts an incremental campaign costing perspective, aiming to capture the additional resources required to implement the TCV campaign, rather than the full economic cost of the immunization system. Accordingly, long-term infrastructure costs were excluded, specifically EPI buildings and office infrastructure. These items were excluded because they were not procured nor expanded specifically for the campaign and are shared with routine immunization activities. We have now explicitly stated this in the Methods section and clarified that the reported economic costs include annualized capital costs for campaign-specific items only (e.g., vehicles and equipment mobilized for the campaign where applicable). MINOR CONCERNS Methods and Reporting Line 72: Specify which TCV vaccine (Typbar TCV® or TYPHIBEV®) was used in Burkina Faso In Burkina Faso, TYPHIBEV® was used for the campaign. Lines 97-98: Standardize terminology as "microcosting" (no hyphen) throughout We used a standard terminology «microcosting» throughout the manuscript. Line 120: Describe replacement protocol for 5 inaccessible CSPS more rigorously. What specific matching criteria were used? Conduct sensitivity analysis excluding these sites. We added a sentence in the methods section to describe more rigorously the replacement protocol of inaccessible facilities as follows (lines 123-127): «Due to security concerns, we replaced five inaccessible CSPS with alternative facilities with similar characteristics. The matching criteria were based on sampling weights derived from catchment area population size and the number of doses delivered, as well as stratification by urban versus rural location.» Furthermore we conducted a scenario analysis excluding these sites This analysis indicated that there was no substantial impact on either financial or economic costs estimates (See lines 270-274). Line 153: Clarify how oral consent was documented Add to Methods: "Reporting follows CHEERS 2022 guidelines for economic evaluations" and include completed checklist as supplementary file Oral consent was obtained prior to each interview after the study objectives and procedures were read aloud to participants. Consent was documented by the data collector’s signature on a standardized form confirming that the information had been provided and that the participant agreed to take part in the study. Also, we added to methods section, a sentence related to CHEERS guidelines and included completed CHEERS checklist as a supplementary file. Reviewer #4: We thank the reviewer for the constructive review of the manuscript The definition of financial cost and economic cost should be included in the introduction because it will give the reader a better understanding of t Submitted filename: Responses to reviewers.docx 10 May 2026 -->PONE-D-25-66817R1-->-->Cost analysis of a nationwide typhoid conjugate vaccine campaign in Burkina Faso-->-->PLOS One Dear Dr. Koulidiati, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.-->--> Please submit your revised manuscript by Jun 24 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. --> If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Leonard Ighodalo Uzairue, PhD Academic Editor PLOS One Journal Requirements: 1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #3: All comments have been addressed Reviewer #4: All comments have been addressed ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #3: Yes Reviewer #4: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #3: Yes Reviewer #4: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #3: Yes Reviewer #4: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #3: Yes Reviewer #4: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #3: The authors have substantively improved the manuscript and addressed most prior concerns. Remaining issues are mostly editorial Reviewer #4: The topic Cost analysis of a nationwide typhoid conjugate vaccine campaign in Burkina Faso. The issues of definition of some terms were addressed and the define them in the introduction section of the paper. I believe that the article can be published. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #3: No Reviewer #4: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. --> Submitted filename: PLOS reviewer.docx 12 May 2026 Dear Editor, We thank you, the PlosOne editorial team and all the reviewers for the constructive comments to our submission. Below, we respond to each comment. Editor and reviewers comments are reproduced in regular font, followed by our responses in bold. Review Comments to the Author Reviewer #3: The authors have substantively improved the manuscript and addressed most prior concerns. Remaining issues are mostly editorial We thank the reviewer for their positive assessment and constructive comments. We have carefully reviewed the manuscript and addressed all remaining editorial issues, including formatting consistency, tense agreement, and citation style. Changes are highlighted in the tracked-changes version of the manuscript. Reviewer #4: The topic Cost analysis of a nationwide typhoid conjugate vaccine campaign in Burkina Faso. The issues of definition of some terms were addressed and the define them in the introduction section of the paper. I believe that the article can be published. We thank the reviewer for their review and positive recommendation. Submitted filename: Responses to reviewers_V2.docx 25 May 2026 Cost analysis of a nationwide typhoid conjugate vaccine campaign in Burkina Faso PONE-D-25-66817R2 Dear Koulidiati, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Leonard Ighodalo Uzairue, PhD Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: PONE-D-25-66817R2 PLOS One Dear Dr. Koulidiati, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Leonard Ighodalo Uzairue Academic Editor PLOS One